Tirzepatide labeling handles a late injection cleanly. A missed weekly dose can be given within four days, and after that window it is skipped, with the next injection landing on the usual day. Doubling up is not part of the instruction. What the label cannot address is a gap created deliberately to make a supply last longer.
The gap and the stretching attempt are one problem
People rarely set out to miss a week. They set out to make four weeks of medication cover six, and the missed week is what that plan produces once the supply runs out early or the container reaches its discard date. Treating the two as separate events hides the cause, which is usually cost, a coverage change, or a shipment that did not arrive.
That distinction matters for the conversation afterward. A forgotten injection is solved by a reminder. A gap produced by rationing is solved by changing the price, the channel, or the coverage, and nothing about how the drug is administered touches it at all.
Because channel is so often the real cause, it is worth knowing how the main names handle resupply and information. LillyDirect connects patients to the branded product through the manufacturer, and telehealth options such as Ro, Hims & Hers, and HealthRX post their own pages on Mounjaro alongside their reorder and shipping terms. Reading how far ahead each one refills, and how plainly it states the dosing schedule, separates a service built around continuity from one that invites the next gap.
What the label sets out, and what it does not
Two rules cover timing. A dose taken late is given within four days of the scheduled day, and beyond that it is skipped rather than added to the next one. The weekly day itself can be moved if needed, provided at least three days separate the two injections involved in the change. Both rules exist to keep exposure inside the range the weekly schedule produces, and neither creates a route to catching up.
Nothing in the label describes reducing an amount to bridge a shortfall, because there is no labeled amount below the 2.5 mg initiation step and no presentation that delivers one. The single-dose pen is printed for use one time each week. The KwikPen holds four fixed doses and its instructions for use tell patients not to transfer product from the pen into a syringe. Those are the boundaries a bridging plan runs into immediately.
Discard dates create gaps of their own
Storage rules put a clock on any product already in the house. A single-dose pen or single-dose vial kept at room temperature is discarded after a total of 21 days, and the vial instructions direct that opened vials are thrown away after use even with medicine remaining, because those presentations carry no antimicrobial preservative. A multi-dose vial or KwikPen is discarded after four weekly doses, after 30 days at room temperature, or 30 days after first use, whichever arrives first.
Anyone planning to spread a supply across extra weeks therefore collides with a date, not just with arithmetic. Product held past those windows is outside the conditions under which its stability and sterility were established, which turns a saving into a discarded box.
What the gap actually was, and what resolves it
| Reason the week was missed | What it really is | What resolves it |
|---|---|---|
| Refill cost more than expected | A pricing problem | Self-pay channel, savings program, formulary check |
| Claim denied at the counter | A coverage problem | Internal appeal, then external review |
| Shipment arrived late | A service problem | Earlier reorder trigger, confirmed with the provider |
| Supply stretched on purpose | A budget problem wearing a dosing costume | Naming the real figure so the plan can change |
| Symptoms made the injection unappealing | A tolerability problem | Holding at the tolerated step instead of skipping |
| Product passed its discard date | A storage window problem | Matching refill timing to the labeled window |
| Travel disrupted the schedule | A logistics problem | Moving the weekly day within the labeled separation |
Coming back after a longer break
A single skipped week is administratively simple. Several weeks away is not, because the tolerance built during escalation is the thing most likely to have faded. The label records that gastrointestinal reactions concentrate during dose escalation and decrease with continued treatment, which implies the reverse deserves thought after an interruption. Whether someone resumes at the step they left or steps back is a prescriber decision made with the record in front of them.
Two items belong in that conversation regardless. Anyone taking insulin or an insulin secretagogue such as a sulfonylurea should confirm whether those doses were adjusted while tirzepatide was paused, since hypoglycemia risk rises when the combination resumes. Anyone whose gap was caused by symptoms should say so directly, because the labeled response to poor tolerability is holding at a step rather than resuming a climb.
Where the prescription comes from changes the failure mode
Refill cadence is the single most common cause of an unplanned gap, and it varies by channel. A retail pharmacy prescription depends on prior authorization status and stock. LillyDirect connects patients to a prescriber and ships the branded product. Direct-to-consumer services including Ro, Hims & Hers, LifeMD, WeightWatchers Clinic, and FormBlends set their own reorder triggers, and a service that ships only after the last dose is used will generate missed weeks no matter how organized the patient is. Asking how far ahead a reorder goes out, and what happens when a shipment is delayed, is worth doing before the first gap rather than after.
One response makes things reliably worse: buying a substitute from an unfamiliar seller to bridge the wait. The FDA maintains guidance on identifying legitimate online pharmacies and has documented counterfeit products reaching patients, and a purchase made under time pressure is exactly where that risk concentrates. Compounded tirzepatide is a separate matter again, since it is not FDA-approved and its concentration varies by pharmacy, so instructions for one preparation do not describe another.
Frequently asked questions
Can a smaller amount be given to make a supply reach the next refill?
No approved presentation delivers less than a labeled dose, and there is no validated home method for producing one. The route people ask about most often, drawing from a pen, is addressed directly in the KwikPen instructions for use, which say not to transfer product from the pen into a syringe.
How late is too late for a missed injection?
The label allows a dose to be given within four days of the scheduled day. Past that point it is skipped and the schedule resumes on the normal day. The instruction never involves adding the missed dose to the next one, and a separate rule keeps at least three days between any two injections.
Does a missed week undo the previous month of treatment?
Not mechanically. Tirzepatide reaches steady state over roughly four weeks of weekly dosing and a single gap does not reset that. What can change after a longer break is gastrointestinal tolerance, which is why an extended interruption tends to prompt a discussion about which step to resume at.
Is leftover medicine in a used container worth keeping?
The instructions for use answer that: opened single-dose vials are discarded after use even when medicine remains, and multi-dose presentations are discarded after four weekly doses or 30 days from first use. Storage windows are part of how sterility and stability were established, so product kept past them sits outside tested conditions.